Anticoagulants

Core Concepts

Unfractionated heparin: the antithrombin booster

Heparin binds to antithrombin III, a natural anticoagulant protein, and accelerates its inactivation of clotting factors — most importantly thrombin (factor IIa) and factor Xa. It acts quickly, has a short duration of action, and suits hospital settings, bridging therapy, and surgery. It is traditionally monitored with the aPTT test (verify current practice and targets against institutional policy). Bleeding is the main risk, and protamine sulfate can reverse heparin by binding and neutralizing it — an exam favorite.

LMWHs and fondaparinux

LMWHs (e.g., enoxaparin) are heparin fragments that retain acceleration of antithrombin's inactivation of factor Xa but have less effect on thrombin. Their kinetics are more predictable, they are given subcutaneously, and they generally need less laboratory monitoring. Fondaparinux is a synthetic version of heparin's antithrombin-binding sequence — purely anti-Xa. An educational caveat: protamine does not fully reverse LMWHs and does not reverse fondaparinux, so bleeding management differs — verify reversal strategies against current references and protocols.

Warfarin: the vitamin K antagonist

Warfarin blocks vitamin K epoxide reductase, the enzyme that recycles vitamin K in the liver; without recycled vitamin K, the liver cannot activate factors II, VII, IX, and X (nor proteins C and S). Because the body must use up already-activated factors, warfarin's onset takes days — why it is often started alongside a fast-acting parenteral agent until the INR reaches target. It is monitored with PT/INR, has many drug and food interactions (especially dietary vitamin K), and crosses the placenta, so its use in pregnancy is heavily restricted — verify current guidance. Bleeding is reversed with vitamin K and, in serious cases, clotting-factor replacement products per current protocols.

Direct oral anticoagulants (DOACs)

The DOACs inhibit a single step directly, giving more predictable pharmacology than warfarin: dabigatran directly inhibits thrombin (factor IIa); rivaroxaban, apixaban, and edoxaban directly inhibit factor Xa. DOACs have rapid onset, short half-lives, and, in most stable outpatient situations, fixed dosing without routine lab monitoring — though kidney function matters, since several are renally cleared. Specific reversal agents exist for serious bleeding (e.g., idarucizumab for dabigatran; andexanet alfa for the Xa inhibitors), but availability varies by institution — verify. DOACs are generally avoided in pregnancy and with mechanical heart valves; check current product information.

Nursing care across the class

• Bleeding-risk assessment: identify higher-risk people (recent surgery or trauma, kidney or liver disease, concurrent antiplatelets, falls risk) and watch for bruising, bleeding gums, dark stools, blood in urine, or unusual headache.
• Monitoring: know which drugs need lab monitoring (warfarin → INR; UFH → aPTT in many settings) and what the institution's protocol says — never rely on memory for targets.
• Education: teach people to report unusual bleeding, carry medication ID, keep monitoring appointments, and ask before adding any new drug or product.
• Adherence and coordination: missed or double doses are high-risk events, and surgery or spinal/epidural procedures require coordinated planning — always follow institutional policy and prescriber orders.

Common Confusions